IM Cannabis (IMCC) Prnewswire·2025-03-20 11:00Core Insights - IM Cannabis Corp. will report its operational and financial results for Q4 and full year 2024 on March 31, 2025, before market opens [1] - A Zoom web conference will be held on the same day at 9:00 a.m. ET to discuss the results, followed by a Q&A session for investors [2] Company Overview - IM Cannabis Corp. is a leading international cannabis company focused on providing premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets [3] - The company aims for sustainable and profitable growth in its highest value markets, leveraging a data-driven approach and a globally sourced product supply chain [3] - IM Cannabis is committed to responsible growth and compliance with strict regulatory environments to enhance its commercial and brand power [3] Operational Ecosystem - In Israel, IM Cannabis operates through a partnership with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, utilizing proprietary data and patient insights [4] - The company also runs medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel to ensure safe delivery and quality control of its products [4] - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [4]